EMA concludes defective device in ROCKET study does not impact Xarelto's safety

View source ↗

Summary

EMA states that a defective device in the ROCKET study does not impact the safety of Xarelto (rivaroxaban).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Dvt
• Pulmonary Embolism
• Venous Thromboembolism

Drugs mentioned

• Xarelto (rivaroxaban)